MX355104B - Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos. - Google Patents

Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos.

Info

Publication number
MX355104B
MX355104B MX2014011921A MX2014011921A MX355104B MX 355104 B MX355104 B MX 355104B MX 2014011921 A MX2014011921 A MX 2014011921A MX 2014011921 A MX2014011921 A MX 2014011921A MX 355104 B MX355104 B MX 355104B
Authority
MX
Mexico
Prior art keywords
preparation
processes
therapeutic uses
thienopyrimidine derivatives
novel thienopyrimidine
Prior art date
Application number
MX2014011921A
Other languages
English (en)
Other versions
MX2014011921A (es
Inventor
Duclos Olivier
Mallart Sergio
Carry Jean-Christophe
Chatreaux Fabienne
Deprets Stéphanie
Leroy Vincent
Melon-Manguer Dominique
Mendez-Perez Maria
Vergne Fabrice
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48095815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355104(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2014011921A publication Critical patent/MX2014011921A/es
Publication of MX355104B publication Critical patent/MX355104B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I): (ver Fórmula) en la que R6 es -CONH2 o un grupo -C(Ra)(Rß)(OH); R es un grupo fenilo o heteroarilo sustituido; R7 es un grupo arilo o heteroarilo opcionalmente sustituido. Procesos para su preparación y su uso terapéutico.
MX2014011921A 2012-04-03 2013-04-02 Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos. MX355104B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1253044A FR2988722B1 (fr) 2012-04-03 2012-04-03 Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
PCT/EP2013/056958 WO2013150036A1 (en) 2012-04-03 2013-04-02 Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
MX2014011921A MX2014011921A (es) 2015-02-24
MX355104B true MX355104B (es) 2018-04-05

Family

ID=48095815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011921A MX355104B (es) 2012-04-03 2013-04-02 Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos.

Country Status (37)

Country Link
US (6) US9115140B2 (es)
EP (1) EP2834248B1 (es)
JP (1) JP6096278B2 (es)
KR (1) KR102039764B1 (es)
CN (2) CN107652303B (es)
AR (1) AR090572A1 (es)
AU (1) AU2013244992B2 (es)
BR (1) BR112014024489B1 (es)
CA (1) CA2868685C (es)
CL (1) CL2014002661A1 (es)
CO (1) CO7091179A2 (es)
CR (1) CR20140435A (es)
CY (1) CY1117843T1 (es)
DK (1) DK2834248T3 (es)
DO (1) DOP2014000216A (es)
EA (1) EA025558B1 (es)
ES (1) ES2577382T3 (es)
FR (1) FR2988722B1 (es)
HR (1) HRP20160649T1 (es)
HU (1) HUE027895T2 (es)
IL (1) IL234960A (es)
MA (1) MA37384B1 (es)
MX (1) MX355104B (es)
MY (1) MY166151A (es)
PE (1) PE20150289A1 (es)
PH (1) PH12014502180B1 (es)
PL (1) PL2834248T3 (es)
PT (1) PT2834248E (es)
RS (1) RS54850B1 (es)
SG (1) SG11201406091RA (es)
SI (1) SI2834248T1 (es)
TN (1) TN2014000415A1 (es)
TW (1) TWI579288B (es)
UA (1) UA112685C2 (es)
UY (1) UY34725A (es)
WO (1) WO2013150036A1 (es)
ZA (1) ZA201407021B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
US10087195B2 (en) * 2014-05-28 2018-10-02 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2016169504A1 (zh) * 2015-04-24 2016-10-27 广州再极医药科技有限公司 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
WO2017114351A1 (en) * 2015-12-27 2017-07-06 Chongqing Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
DK3452484T3 (da) * 2016-05-07 2023-09-25 Fochon Pharmaceuticals Ltd Visse protein-kinase-inhibitorer
EP3682881A4 (en) 2017-09-14 2021-08-11 Daiichi Sankyo Company, Limited CONNECTION WITH CYCLICAL STRUCTURE
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
CN110551142B (zh) * 2018-05-31 2023-05-12 上海再极医药科技有限公司 一种稠环嘧啶类化合物的盐、晶型及其制备方法和应用
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110922421B (zh) * 2019-12-17 2023-05-05 安徽英特美科技有限公司 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
WO2021180032A1 (en) * 2020-03-13 2021-09-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Novel Therapeutic Methods
WO2023169461A1 (zh) * 2022-03-08 2023-09-14 广州再极医药科技有限公司 一种噻吩并嘧啶类化合物、中间体、其制备方法、组合物和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BR9814018A (pt) 1997-11-11 2000-09-26 Pfizer Prod Inc Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
DE10042997A1 (de) 2000-09-01 2002-03-14 Merck Patent Gmbh Thienopyrimidine
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
PT2091918E (pt) 2006-12-08 2014-11-24 Irm Llc Compostos e composições como inibidores de proteína cinase
PL2215094T3 (pl) * 2007-11-15 2016-09-30 Związki heterocykliczne zawierające n
DE102008017853A1 (de) * 2008-04-09 2009-10-15 Merck Patent Gmbh Thienopyrimidine
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
KR101094446B1 (ko) * 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노[3,2-d]피리미딘 화합물
WO2012004900A1 (en) 2010-07-09 2012-01-12 Aska Pharmaceutical Co., Ltd. Thienopyrimidine compounds
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques

Also Published As

Publication number Publication date
CN107652303A (zh) 2018-02-02
KR102039764B1 (ko) 2019-11-01
AU2013244992A1 (en) 2014-10-23
US9115140B2 (en) 2015-08-25
BR112014024489B1 (pt) 2020-11-10
SI2834248T1 (sl) 2016-07-29
US10736904B2 (en) 2020-08-11
HK1248214A1 (zh) 2018-10-12
IL234960A (en) 2017-06-29
AU2013244992B2 (en) 2017-04-20
UA112685C2 (uk) 2016-10-10
CN107652303B (zh) 2020-08-04
US20130261106A1 (en) 2013-10-03
PH12014502180A1 (en) 2014-12-10
PH12014502180B1 (en) 2014-12-10
TN2014000415A1 (en) 2015-12-21
CY1117843T1 (el) 2017-05-17
TWI579288B (zh) 2017-04-21
JP6096278B2 (ja) 2017-03-15
KR20150001781A (ko) 2015-01-06
DOP2014000216A (es) 2017-09-15
US10500212B2 (en) 2019-12-10
EP2834248A1 (en) 2015-02-11
DK2834248T3 (en) 2016-07-04
JP2015512434A (ja) 2015-04-27
FR2988722B1 (fr) 2014-05-09
US10220044B2 (en) 2019-03-05
PE20150289A1 (es) 2015-03-05
MA37384B1 (fr) 2017-03-31
US20170319594A1 (en) 2017-11-09
FR2988722A1 (fr) 2013-10-04
MA37384A1 (fr) 2016-06-30
CA2868685A1 (en) 2013-10-10
MX2014011921A (es) 2015-02-24
HUE027895T2 (en) 2016-10-28
CL2014002661A1 (es) 2014-12-26
MY166151A (en) 2018-06-06
EA025558B1 (ru) 2017-01-30
US20150352124A1 (en) 2015-12-10
PT2834248E (pt) 2016-06-24
US20200323874A1 (en) 2020-10-15
PL2834248T3 (pl) 2016-09-30
US20200078370A1 (en) 2020-03-12
TW201345914A (zh) 2013-11-16
AR090572A1 (es) 2014-11-19
US9744176B2 (en) 2017-08-29
CN104540834B (zh) 2017-11-14
HRP20160649T1 (hr) 2016-07-15
HK1201263A1 (zh) 2015-08-28
EP2834248B1 (en) 2016-03-16
WO2013150036A1 (en) 2013-10-10
US10980816B2 (en) 2021-04-20
UY34725A (es) 2013-09-30
ES2577382T3 (es) 2016-07-14
CN104540834A (zh) 2015-04-22
US20190151330A1 (en) 2019-05-23
CR20140435A (es) 2015-03-13
CO7091179A2 (es) 2014-10-21
ZA201407021B (en) 2015-11-25
CA2868685C (en) 2021-01-12
EA201491820A1 (ru) 2015-02-27
SG11201406091RA (en) 2014-10-30
RS54850B1 (sr) 2016-10-31

Similar Documents

Publication Publication Date Title
MX355104B (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos.
PH12012501650B1 (en) Heterocyclic compound
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
IN2014MN02496A (es)
MX352928B (es) Compuestos de piridazina-amida.
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
MX2013015308A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
MX349548B (es) Compuestos de tienopirimidina.
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
MX346095B (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
IN2014DN00144A (es)
MX364400B (es) Compuestos de tetraciclina.
JO3196B1 (ar) عملية تحضير ملح ل – ارجينين البيريندوبريل
GEP201706655B (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
WO2012140490A3 (en) Processes for preparing pitavastatin calcium
WO2014087208A3 (en) A process of preparing alcaftadine
MX2015002705A (es) Compuestos de piridinona para usarse en terapia fotodinamica.
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
AU2013237020A8 (en) Sulphonamide derivatives of benzylamine for the treatment of CNS diseases
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
NZ724424A (en) Pyrimidine derivatives for the treatment of bacterial diseases
IN2014DN07498A (es)
JO3723B1 (ar) مركبات دائرية مغايرة

Legal Events

Date Code Title Description
FG Grant or registration